See more : Vinci SA (VCISY) Income Statement Analysis – Financial Results
Complete financial analysis of Perpetua Resources Corp. (PPTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perpetua Resources Corp., a leading company in the Other Precious Metals industry within the Basic Materials sector.
You may be interested
- Array Technologies, Inc. (ARRY) Income Statement Analysis – Financial Results
- Northstar Clean Technologies Inc. (ROOOF) Income Statement Analysis – Financial Results
- LGB Forge Limited (LGBFORGE.NS) Income Statement Analysis – Financial Results
- Tung Ho Steel Enterprise Corporation (2006.TW) Income Statement Analysis – Financial Results
- Kingland Property Corporation Ltd. (6264.TWO) Income Statement Analysis – Financial Results
Perpetua Resources Corp. (PPTA)
About Perpetua Resources Corp.
Perpetua Resources Corp. engages in the mineral exploration activities in the United States. The company primarily explores for gold, silver, and antimony. Its principal asset is the 100% owned Stibnite gold project located in Valley County, Idaho. The company was formerly known as Midas Gold Corp. and changed its name to Perpetua Resources Corp. in February 2021. Perpetua Resources Corp. was incorporated in 2011 and is headquartered in Boise, Idaho.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 981.91K | 61.29K | 58.92K | 284.41K | 249.30K | 267.09K | 639.73K | 1.03M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -981.91K | -61.29K | -58.92K | -284.41K | -249.30K | -267.09K | -639.73K | -1.03M | -1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.15K | 9.58M | 18.51M | 4.42M | 4.12M | 3.07M | 3.59M | 2.67M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Selling & Marketing | 31.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.82M | 9.58M | 18.51M | 4.42M | 4.12M | 3.07M | 3.59M | 2.67M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Other Expenses | -74.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.45M | 0.00 |
| Operating Expenses | -40.27M | 29.24M | 41.23M | 29.67M | 30.99M | 28.14M | 24.56M | 11.69M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Cost & Expenses | -40.27K | 29.30M | 41.29M | 29.96M | 31.24M | 28.41M | 25.20M | 12.72M | 1.98M | 2.42M | 3.91M | 7.81M | 11.27M | 611.03K |
| Interest Income | 442.94K | 485.47K | 58.31K | 277.82K | 548.04K | 636.72K | 293.55K | 215.08K | 23.15K | 56.57K | 84.63K | 197.72K | 276.46K | 22.83K |
| Interest Expense | 0.00 | 0.00 | 362.55K | 3.16M | 2.71M | 2.48M | 2.23M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 981.91K | 4.63M | 12.26M | 284.41K | 249.30K | 267.09K | 639.73K | 1.03M | 8.94K | 25.38K | 34.27K | 35.32K | 10.23K | 0.00 |
| EBITDA | -17.79M | -24.09M | -23.33M | -29.51M | -8.34M | -44.55M | -24.18M | -11.37M | -9.73M | -2.02M | -3.76M | -7.14M | -13.09M | -542.57K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 40.27K | -29.33M | 41.29M | 29.96M | 31.24M | -28.41M | -25.20M | -12.72M | -1.98M | -2.42M | -3.91M | -7.81M | -11.27M | -611.03K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -18.81M | -58.05M | -77.24M | -190.67M | 19.94M | -18.88M | 16.91M | -33.44M | 681.92K | 1.84M | 111.97K | 633.17K | -2.45M | 0.00 |
| Income Before Tax | -18.77M | -28.71M | -35.95M | -220.63M | -11.30M | -47.29M | -8.29M | -46.16M | -1.30M | -573.75K | -3.80M | -7.18M | -13.71M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -167.19K | 362.55K | 3.16M | 2.71M | 2.48M | 2.23M | 1.68M | -681.92K | -1.84M | -111.97K | -633.17K | -276.46K | 588.19K |
| Net Income | -18.77M | -28.71M | -35.95M | -220.63M | -11.30M | -47.29M | -8.29M | -46.16M | -1.30M | -573.75K | -3.80M | -7.18M | -13.44M | -588.19K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.46 | -0.66 | -6.45 | -0.44 | -2.18 | -0.45 | -2.65 | -0.08 | -0.04 | -0.31 | -0.64 | -1.59 | -0.15 |
| EPS Diluted | -0.30 | -0.46 | -0.66 | -6.45 | -0.44 | -2.18 | -0.45 | -2.65 | -0.08 | -0.04 | -0.31 | -0.64 | -1.59 | -0.15 |
| Weighted Avg Shares Out | 63.19M | 62.99M | 54.53M | 34.23M | 25.46M | 21.69M | 18.40M | 17.40M | 15.35M | 13.93M | 12.11M | 11.27M | 8.47M | 3.82M |
| Weighted Avg Shares Out (Dil) | 63.19M | 62.99M | 54.53M | 34.23M | 25.46M | 21.69M | 18.40M | 17.40M | 15.35M | 13.93M | 12.11M | 11.27M | 8.47M | 3.82M |
Zika Virus Guidance from FDA Notes Safety of Plasma Protein Products and the Availability of Octapharma’s Octaplas™
HOBOKEN, N.J.--(BUSINESS WIRE)--Global health concerns regarding the Zika virus (ZIKV), a flavivirus, have prompted the U.S. Food and Drug Administration (FDA) to issue guidance for blood donation collection, recommending that donors at risk for the virus defer donations for four...
Technavio Publishes New Market Analysis on Global Plasma Therapeutics Market from 2015-2019
LONDON--(BUSINESS WIRE)--Technavio has published a new report on the global plasma therapeutics market, which is expected to grow at a CAGR of more than 12% from 2015-2019. About the Report The new report by Technavio draws attention towards organizations such...
Baxter Supports IPOPI Initiative to Improve Global Care of Primary Immunodeficiencies During 5th Annual World PI Week
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) is celebrating the fifth annual World Primary Immunodeficiency Week Campaign, April 22 – 29, 2015, by collaborating with the International Patient Organisation for Primary Immunodeficiencies (IPOPI) to advance the global state of care for...
Source: https://incomestatements.info
Category: Stock Reports